Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorthalidone

FDA-approved product (tablet, oral), marketed as Chlorthalidone, Hemiclor, Hygroton and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Chlorthalidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Congestive heart failure
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorthalidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorthalidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

    NCT03923933 · start 2019-06-18

    Registered record
    Registry ID
    NCT03923933
    Conditions
    Renal Insufficiency, Chronic
    Interventions
    Chlorthalidone; Bumetanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-06-18
    Completion
    2019-10-28
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency, Chronic
    InterventionChlorthalidone; Bumetanide
    PhasePhase 2
    Registry statusCompleted

  • Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions

    NCT05090449 · start 2019-05-01

    Registered record
    Registry ID
    NCT05090449
    Conditions
    Healthy
    Interventions
    Chlorthalidone (HIGROTON® 50); Losartan (COZZAR®); A1+ A2 Co-administration of Chlorthalidone and Losartan; Chlorthalidone + Losartan Fixed-Dose combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-05-01
    Completion
    2020-05-25
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionChlorthalidone (HIGROTON® 50); Losartan (COZZAR®); A1+ A2 Co-administration of Chlorthalidone and Losartan; Chlorthalidone + Losartan Fixed-Dose combination
    PhasePhase 1
    Registry statusCompleted

  • The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.

    NCT04393493 · start 2017-07-01

    Registered record
    Registry ID
    NCT04393493
    Conditions
    Cardiorenal Syndrome
    Interventions
    Furosemide intravenous solution; Chlortalidone; Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-01
    Completion
    2020-04-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiorenal Syndrome
    InterventionFurosemide intravenous solution; Chlortalidone; Spironolactone
    PhasePhase 2
    Registry statusCompleted

  • Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.

    NCT03006796 · start 2017-01-16

    Registered record
    Registry ID
    NCT03006796
    Conditions
    Arterial Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-01-16
    Completion
    2020-03-31
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

    NCT02521246 · start 2016-11

    Registered record
    Registry ID
    NCT02521246
    Conditions
    Essential Arterial Hypertension
    Interventions
    Candesartan + Chlorthalidone; Candesartan + Chlorthalidone; Losartan+hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-11
    Completion
    2017-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Arterial Hypertension
    InterventionCandesartan + Chlorthalidone; Candesartan + Chlorthalidone; Losartan+hydrochlorothiazide
    PhasePhase 3
    Registry statusWithdrawn

  • Comparison of Optimal Hypertension Regimens

    NCT02847338 · start 2016-11

    Registered record
    Registry ID
    NCT02847338
    Conditions
    Hypertension
    Interventions
    Amlodipine; Lisinopril; Amiloride; Chlortalidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-11
    Completion
    2023-10
    Enrolment
    940

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmlodipine; Lisinopril; Amiloride; Chlortalidone
    PhasePhase 4
    Registry statusCompleted

  • OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)

    NCT02814552 · start 2016-06-18

    Registered record
    Registry ID
    NCT02814552
    Conditions
    High Blood Pressure
    Interventions
    HTN PRA App; Blood Sample
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-06-18
    Completion
    2018-06-30
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Blood Pressure
    InterventionHTN PRA App; Blood Sample
    PhaseNot applicable
    Registry statusCompleted

  • Diuretic Comparison Project

    NCT02185417 · start 2016-06-15

    Registered record
    Registry ID
    NCT02185417
    Conditions
    Hypertension
    Interventions
    Hydrochlorothiazide (HCTZ); Chlorthalidone (CTD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-06-15
    Completion
    2022-12-29
    Enrolment
    20,723

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionHydrochlorothiazide (HCTZ); Chlorthalidone (CTD)
    PhasePhase 3
    Registry statusCompleted

  • S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

    NCT03226340 · start 2015-12-02

    Registered record
    Registry ID
    NCT03226340
    Conditions
    Essential Hypertension
    Interventions
    S-amlodipine 2.5mg + Chlorthalidone 25mg; S-amlodipine 2.5mg + Telmisartan 40mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-12-02
    Completion
    2018-03-31
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionS-amlodipine 2.5mg + Chlorthalidone 25mg; S-amlodipine 2.5mg + Telmisartan 40mg
    PhasePhase 4
    Registry statusUnknown

  • Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

    NCT02620163 · start 2015-12

    Registered record
    Registry ID
    NCT02620163
    Conditions
    Hypertension
    Interventions
    telmisartan/amlodipine 40/5mg; YH22162 40/5/12.5 mg; telmisartan/amlodipine 80/5mg; YH22162 80/5/25 mg; telmisartan/amlodipine 40/5mg placebo; YH22162 40/5/12.5 mg placebo; telmisartan/amlodipine 80/5mg placebo; YH22162 80/5/25 mg placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-12
    Enrolment
    381

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventiontelmisartan/amlodipine 40/5mg; YH22162 40/5/12.5 mg; telmisartan/amlodipine 80/5mg; YH22162 80/5/25 mg +4 more
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study

    NCT02591628 · start 2015-08

    Registered record
    Registry ID
    NCT02591628
    Conditions
    Hypertension
    Interventions
    HCTZ prescription conversion to chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-08
    Completion
    2017-07
    Enrolment
    2,027

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionHCTZ prescription conversion to chlorthalidone
    PhaseNot applicable
    Registry statusCompleted

  • Mechanisms of Refractory Hypertension (Carvedilol)

    NCT02357004 · start 2015-02

    Registered record
    Registry ID
    NCT02357004
    Conditions
    Hypertensive
    Interventions
    Carvedilol; Chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2015-02
    Completion
    2020-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive
    InterventionCarvedilol; Chlorthalidone
    PhaseNot applicable
    Registry statusWithdrawn

  • Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

    NCT02665117 · start 2015-01

    Registered record
    Registry ID
    NCT02665117
    Conditions
    Hypertension
    Interventions
    Potassium Magnesium Citrate (KMgCit); Potassium Chloride (KCl); Chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01
    Completion
    2022-11-04
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionPotassium Magnesium Citrate (KMgCit); Potassium Chloride (KCl); Chlorthalidone
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea

    NCT02896621 · start 2014-12-07

    Registered record
    Registry ID
    NCT02896621
    Conditions
    Hypertension; Sleep Apnea
    Interventions
    Chlorthalidone plus amiloride; Amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12-07
    Completion
    2017-02-14
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Sleep Apnea
    InterventionChlorthalidone plus amiloride; Amlodipine
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

    NCT02232880 · start 2014-08

    Registered record
    Registry ID
    NCT02232880
    Conditions
    Hypertension
    Interventions
    Abatacept; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-08
    Completion
    2015-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAbatacept; Placebo
    PhasePhase 2
    Registry statusTerminated